Financial Statements Consolidated Statement of Comprehensive Income for the year ended 31 December 2014 2013 2015 Restated Restated Notes $m $m $m Product Sales 1 23,641 26,095 25,711 Externalisation Revenue 1 1,067 452 95 Total Revenue 24,708 26,547 25,806 Cost of sales 4,646 5,842 5,261 Gross profit 20,062 20,705 20,545 Distribution costs 339 324 306 Research and development expense 2 5,997 5,579 4,821 Selling, general and administrative costs 2 11,112 13,000 12,206 Other operating income and expense 2 1,500 335 500 Operating profit 4,114 2,137 3,712 Finance income 3 46 78 50 Finance expense 3 1,075 963 495 Share of after tax losses in joint ventures 10 16 6 Profit before tax 3,069 1,246 3,267 Taxation 4 243 11 696 Profit for the period 2,826 1,235 2,571 Other comprehensive income: Items that will not be reclassified to profit or loss: Remeasurement of the defined benefit pension liability 20 652 766 8 Tax on items that will not be reclassified to profit or loss 4 199 216 82 453 550 74 Items that may be reclassified subsequently to profit or loss: Foreign exchange arising on consolidation 21 528 823 166 Foreign exchange arising on designating borrowings in net investment hedges 21 333 529 58 Fair value movements on derivatives designated in net investment hedges 21 14 100 111 Amortisation of loss on cash flow hedge 1 1 1 Net available for sale losses gains taken to equity 32 245 69 Tax on items that may be reclassified subsequently to profit or loss 4 87 50 4 791 956 39 Other comprehensive income for the period, net of tax 338 1,506 113 Total comprehensive income for the period 2,488 271 2,458 Profit attributable to: Owners of the Parent 2,825 1,233 2,556 Non-controlling interests 1 2 15 Total comprehensive income attributable to: Owners of the Parent 2,488 266 2,470 Non-controlling interests 5 12 Basic earnings per $0.25 Ordinary Share 5 $2.23 $0.98 $2.04 Diluted earnings per $0.25 Ordinary Share 5 $2.23 $0.98 $2.04 Weighted average number of Ordinary Shares in issue millions 5 1,264 1,262 1,252 Diluted weighted average number of Ordinary Shares in issue millions 5 1,265 1,264 1,254 Dividends declared and paid in the period 23 3,537 3,532 3,499 2013 and 2014 comparatives have been restated to reflect the reclassification of Externalisation Revenue from other operating income and expense as detailed in Group Accounting Policies.
All activities were in respect of continuing operations.
$m means millions of US dollars.
140 AstraZeneca Annual Report and Form 20-F Information 2015 Financial Statements Consolidated Statement of Financial Position at 31 December 2015 2014 2013 Notes $m $m $m Assets Non-current assets Property, plant and equipment 7 6,413 6,010 5,818 Goodwill 8 11,868 11,550 9,981 Intangible assets 9 22,646 20,981 16,047 Investments in joint ventures 10 85 59 Other investments 11 458 502 281 Derivative financial instruments 12 446 465 365 Other receivables 13 907 1,112 1,867 Deferred tax assets 4 1,294 1,219 1,205 44,117 41,898 35,564 Current assets Inventories 14 2,143 1,960 1,909 Trade and other receivables 15 6,622 7,232 7,879 Other investments 11 613 795 796 Derivative financial instruments 12 2 21 40 Income tax receivable 387 329 494 Cash and cash equivalents 16 6,240 6,360 9,217 16,007 16,697 20,335 Total assets 60,124 58,595 55,899 Liabilities Current liabilities Interest-bearing loans and borrowings 17 916 2,446 1,788 Trade and other payables 18 11,663 11,886 10,362 Derivative financial instruments 12 9 21 2 Provisions 19 798 623 823 Income tax payable 1,483 2,354 3,076 14,869 17,330 16,051 Non-current liabilities Interest-bearing loans and borrowings 17 14,137 8,397 8,588 Derivative financial instruments 12 1 1 Deferred tax liabilities 4 2,733 1,796 2,827 Retirement benefit obligations 20 1,974 2,951 2,261 Provisions 19 444 484 566 Other payables 18 7,457 7,991 2,352 26,746 21,619 16,595 Total liabilities 41,615 38,949 32,646 Net assets 18,509 19,646 23,253 Equity Capital and reserves attributable to equity holders of the Company Share capital 22 316 316 315 Share premium account 4,304 4,261 3,983 Capital redemption reserve 153 153 153 Merger reserve 448 448 433 Other reserves 21 1,435 1,420 1,380 Retained earnings 21 11,834 13,029 16,960 18,490 19,627 23,224 Non-controlling interests 19 19 29 Total equity 18,509 19,646 23,253 The Financial Statements from page 140 to 195 were approved by the Board on 4 February 2016 and were signed on its behalf by Pascal Soriot Marc Dunoyer Director Director AstraZeneca Annual Report and Form 20-F Information 2015 141 Financial Statements Consolidated Statement of Changes in Equity for the year ended 31 December Share Capital Total NonShare premium redemption Merger Other Retained attributable controlling Total capital account reserve reserve reserves earnings to owners interests equity $m $m $m $m $m $m $m $m $m At 1 January 2013 312 3,504 153 433 1,374 17,955 23,731 215 23,946 Profit for the period 2,556 2,556 15 2,571 Other comprehensive income 86 86 27 113 1 Transfer to other reserves 6 6 Transactions with owners Dividends 3,499 3,499 3,499 Issue of Ordinary Shares 3 479 482 482 Share-based payments 57 57 57 Transfer from non-controlling interests to payables 6 6 Dividend paid by subsidiary to non-controlling interests 3 3 2 Net acquisition of non-controlling interests 97 97 165 68 Net movement 3 479 6 995 507 186 693 At 31 December 2013 315 3,983 153 433 1,380 16,960 23,224 29 23,253 Profit for the period 1,233 1,233 2 1,235 Other comprehensive income 1,499 1,499 7 1,506 1 Transfer to other reserves 40 40 Transactions with owners Dividends 3,532 3,532 3,532 Issue of Ordinary Shares 1 278 279 279 Share-based payments 93 93 93 Transfer from non-controlling interests to payables 5 5 True-up to Astra AB non-controlling interest buy out 15 15 15 Net movement 1 278 15 40 3,931 3,597 10 3,607 At 31 December 2014 316 4,261 153 448 1,420 13,029 19,627 19 19,646 Profit for the period 2,825 2,825 1 2,826 Other comprehensive income 337 337 1 338 1 Transfer to other reserves 15 15 Transactions with owners Dividends 3,537 3,537 3,537 Issue of Ordinary Shares 43 43 43 Share-based payments 131 131 131 Net movement 43 15 1,195 1,137 1,137 At 31 December 2015 316 4,304 153 448 1,435 11,834 18,490 19 18,509 1 Amounts charged or credited to other reserves relate to exchange adjustments arising on goodwill.
2 Net acquisition of non-controlling interests in 2013 includes acquisitions with cash payments of $110m due in 2014 and disposals with cash of $42m received in 2013.
142 AstraZeneca Annual Report and Form 20-F Information 2015 Financial Statements Consolidated Statement of Cash Flows for the year ended 31 December 2015 2014 2013 Notes $m $m $m Cash flows from operating activities Profit before tax 3,069 1,246 3,267 Finance income and expense 3 1,029 885 445 Share of after tax losses of joint ventures 10 16 6 Depreciation, amortisation and impairment 2,852 3,282 4,583 Decrease increase in trade and other receivables 152 311 383 Increase decrease in inventories 315 108 135 Increase in trade and other payables and provisions 114 2,089 414 Gains on disposal of intangible assets 2 961 Non-cash and other movements 782 865 258 Cash generated from operations 5,174 8,792 8,719 Interest paid 496 533 475 Tax paid 1,354 1,201 844 Net cash inflow from operating activities 3,324 7,058 7,400 Cash flows from investing activities Upfront payments on business acquisitions 24 2,446 3,804 1,158 Payment of contingent consideration on business acquisitions 18 579 657 Purchase of property, plant and equipment 1,328 1,012 742 Disposal of property, plant and equipment 47 158 69 Purchase of intangible assets 1,460 1,740 1,316 Disposal of intangible assets 1,130 35 Purchase of non-current asset investments 57 130 91 Disposal of non-current asset investments 93 59 38 Movement in short-term investments and fixed deposits 283 34 130 Payments to joint ventures 10 45 70 Interest received 123 140 114 Payments made by subsidiaries to non-controlling interests 10 10 Payments received by subsidiaries from non-controlling interests 42 Net cash outflow from investing activities 4,239 7,032 2,889 Net cash outflow inflow before financing activities 915 26 4,511 Cash flows from financing activities Proceeds from issue of share capital 43 279 482 Repayment of obligations under finance leases 42 36 27 Issue of loans 5,928 919 Repayment of loans 884 750 Dividends paid 3,486 3,521 3,461 Hedge contracts relating to dividend payments 51 14 36 Payments to acquire non-controlling interest 102 Movement in short-term borrowings 630 520 5 Net cash inflow outflow from financing activities 878 2,705 3,047 Net decrease increase in cash and cash equivalents in the period 37 2,679 1,464 Cash and cash equivalents at the beginning of the period 6,164 8,995 7,596 Exchange rate effects 76 152 65 Cash and cash equivalents at the end of the period 16 6,051 6,164 8,995 AstraZeneca Annual Report and Form 20-F Information 2015 143
